Tavneos FDA Approval History
Last updated by Judith Stewart, BPharm on Oct 11, 2021.
FDA Approved: Yes (First approved October 7, 2021)
Brand name: Tavneos
Generic name: avacopan
Dosage form: Capsules
Company: ChemoCentryx, Inc.
Treatment for: ANCA-Associated Vasculitis
Tavneos (avacopan) is a complement 5a receptor (C5aR) antagonist for the adjunctive treatment of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.
- ANCA-associated vasculitis is a group of diseases that includes granulomatosis with polyangiitis and microscopic polyangiitis. It is caused by complement-induced neutrophil activation. Neutrophils attack the small blood vessels in organs such as the kidneys, stomach, intestines, and lungs leading to organ damage and failure.
- Tavneos is the first FDA-approved orally-administered inhibitor of the complement 5a receptor (C5aR). It works by blocking the C5aR to inhibit C5a-mediated neutrophil activation.
- Tavneos capsules are taken twice daily, with food.
- Tavneos may cause serious adverse reactions, including hepatotoxicity, serious hypersensitivity reactions, hepatitis B virus (HBV) reactivation, and serious infections.
- Common side effects include nausea, headache, hypertension, diarrhea, vomiting, rash, fatigue, upper abdominal pain, dizziness, increased blood creatinine levels, and paresthesia.
Development timeline for Tavneos
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.